drugset / Trial / NCT04970836

The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort

NCT04970836

Non-randomizedParallel-groupOpen-labelPrevention

Summary

This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs titer\<10 mIU/mL) need to take.

Timeline

Start
2021-08-01
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Engerix-B Vaccine